Your browser doesn't support javascript.
loading
Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry.
Miles, John J; Tan, Mai Ping; Dolton, Garry; Edwards, Emily Sj; Galloway, Sarah Ae; Laugel, Bruno; Clement, Mathew; Makinde, Julia; Ladell, Kristin; Matthews, Katherine K; Watkins, Thomas S; Tungatt, Katie; Wong, Yide; Lee, Han Siean; Clark, Richard J; Pentier, Johanne M; Attaf, Meriem; Lissina, Anya; Ager, Ann; Gallimore, Awen; Rizkallah, Pierre J; Gras, Stephanie; Rossjohn, Jamie; Burrows, Scott R; Cole, David K; Price, David A; Sewell, Andrew K.
Affiliation
  • Miles JJ; Centre for Biodiscovery and Molecular Development of Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia.
  • Tan MP; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Dolton G; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Edwards ES; School of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Galloway SA; Griffith University, Brisbane, Queensland, Australia.
  • Laugel B; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Clement M; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Makinde J; Systems Immunity Research Institute, Cardiff University, Cardiff, United Kingdom.
  • Ladell K; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Matthews KK; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Watkins TS; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Tungatt K; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Wong Y; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Lee HS; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Clark RJ; Systems Immunity Research Institute, Cardiff University, Cardiff, United Kingdom.
  • Pentier JM; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Attaf M; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Lissina A; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Ager A; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Gallimore A; School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia.
  • Rizkallah PJ; School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia.
  • Gras S; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Rossjohn J; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Burrows SR; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Cole DK; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Price DA; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Sewell AK; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
J Clin Invest ; 128(4): 1569-1580, 2018 04 02.
Article in En | MEDLINE | ID: mdl-29528337
ABSTRACT
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic "mimics" using subunits that do not exist in the natural world. We developed a platform based on D-amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus-specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza A virus / Influenza Vaccines / Vaccination / Orthomyxoviridae Infections / Peptide Library / Biomimetic Materials Limits: Animals / Humans Language: En Journal: J Clin Invest Year: 2018 Document type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza A virus / Influenza Vaccines / Vaccination / Orthomyxoviridae Infections / Peptide Library / Biomimetic Materials Limits: Animals / Humans Language: En Journal: J Clin Invest Year: 2018 Document type: Article Affiliation country: Australia